Milestone Pharmaceuticals (MIST)
Commercializes an etripamil nasal spray for acute adult PSVT episodes.
Something off on this page? Send us feedback.
Commercializes CARDAMYST, a self-administered etripamil nasal spray for adults experiencing acute symptomatic PSVT. The medicine is its first commercial product, while the same molecule remains in development for AFib with rapid ventricular rate.
Commercializes CARDAMYST, an FDA-approved etripamil nasal spray that adults self-administer to convert acute symptomatic PSVT episodes to sinus rhythm. The medicine is Milestone’s first commercial product and is available through retail pharmacies.
Etripamil is also in development for AFib with rapid ventricular rate, keeping one molecule at the center of the company’s commercial and development work.
A compact internal team directs vendors and consultants across an outsourced supply chain, from active ingredient production and device assembly to packaging and distribution through wholesalers.
Commercial execution depends on third-party manufacturing, release testing, and distribution, while CARDAMYST remains subject to FDA requirements.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 20, 2026 | Cantor Fitzgerald | Initiate | Overweight | $3 | |
| Apr 10, 2026 | Raymond James | Target | $6 | ||
| Dec 16, 2025 | Wells Fargo | Reiterate | Overweight | $8 | |
| Dec 15, 2025 | H.C. Wainwright | Target | $8 | ||
| Dec 15, 2025 | TD Cowen | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $170.6M · Total debt $141.8M · Total assets $181.6M · Shareholders' equity $18.2M
- Revenue
- $559.0K
- Operating income
- −$25.6M
- Net income
- −$28.6M
No dividends on record.
| Institutions86 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 11.73% | 14.61M shares | |
| Insiders8 holders · as of Apr 20, 2026 | 0.88% | 1.10M shares | |
| Strategic holders1 holder · as of May 15, 2026 | 9.93% | 12.36M shares | |
| Otherremainder | ≈ 77.46% | 96.44M shares |
124.50M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
RTW Investments, LP1Strategic10 percent owner | 9.93% | 12.36M | 13Gfiled May 15, 2026 ↗ |
Pavaki Capital Management LLCInstitution | 7.28% | 9.07M | 13Fas of Jun 30, 2026 |
Adage Capital Management, L.P.Institution | 6.43% | 8.00M | 13Gfiled May 13, 2026 ↗ |
Two Sigma Investments, LPInstitution | 1.64% | 2.04M | 13Fas of Jun 30, 2026 |
Marshall Wace, LLPInstitution | 1.44% | 1.80M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
- RTW Investments, LP's transaction reports restate only vehicles that traded; the 2026 ownership statement (12.36M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 16, 2026 | Joseph Oliveto | director, officer: President and CEO | −36,500 | $2.26 |
| Dec 15, 2025 | Joseph Oliveto | director, officer: President and CEO | −133,054 | $2.32 |
| Jan 26, 2026 | Joseph Oliveto | director, officer: President and CEO | −34,523 | $1.93 |
| Dec 15, 2025 | Amit Hasija | officer: CFO & EVP of Corp. Development | −58,007 | $2.32 |
| Jan 26, 2026 | Amit Hasija | officer: CFO & EVP of Corp. Development | −12,245 | $1.93 |
- Teva (ADR)
Acute PSVT conversion with IV adenosine
- Medtronic
Catheter ablation for AVNRT, a PSVT mechanism
- Boston Scientific
Catheter ablation solutions for AVNRT and AVRT
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Milestone Pharmaceuticals | $1.18 | +0.34% | $146.9M | — | — | 62.7 | — |
| Teva (ADR) | $37.45 | −0.05% | $43.66B | 62.5 | 13.3 | 2.4 | −0.8% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Boston Scientific | $48.42 | +0.09% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Median | 22.7 | 14.6 | 3.1 | +7.5% |